Ocugen, Inc.
(NASDAQ : OCGN)

( )
OCGN PreMarket: $ () as of AM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
MRNAModerna, Inc. 6.89%160.030.0%$1347.19m
AMGNAmgen, Inc. -0.13%249.621.3%$691.62m
NVAXNovavax, Inc. 3.43%201.3480.0%$571.11m
SNSSSunesis Pharmaceuticals, Inc. -1.50%7.880.7%$550.84m
ILMNIllumina, Inc. -1.26%398.073.5%$515.02m
GILDGilead Sciences, Inc. 0.63%65.301.0%$465.35m
REGNRegeneron Pharmaceuticals, Inc. 0.86%481.162.7%$431.65m
VRTXVertex Pharmaceuticals, Inc. 0.55%217.131.9%$373.76m
ALXNAlexion Pharmaceuticals, Inc. 1.02%155.292.0%$316.00m
BIIBBiogen, Inc. -0.15%265.791.7%$265.53m
BNTXBioNTech SE 2.28%132.600.0%$236.33m
EXASEXACT Sciences Corp. -0.67%127.1418.4%$192.79m
NBIXNeurocrine Biosciences, Inc. 2.24%95.054.9%$177.79m
CRSPCRISPR Therapeutics AG 1.85%123.110.6%$176.91m
TWSTTwist Bioscience Corp. 0.87%142.030.0%$150.98m

Company Profile

Ocugen, Inc. engages in the development and commercialization of therapies for eye diseases. Its pipeline includes OCU400, OCU410, OCU200, and COVAXIN. The firm's Modifier Gene Therapy Platform engages to address retinal diseases, including retinitis pigmentosa, leber congenital amaurosis, and dry age-related macular degeneration. The company was founded by Shankar Musunuri and Uday B. Kompella in 2013 and is headquartered in Malvern, PA.